ATE214275T1 - Verwendung von n-methyl-n-((1s)-1-phenyl-2-((3s)- 3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl- acetamid hydrochlorid zur herstellung von arzneimitteln zur behandlung von entzündlichen darmerkrankungen - Google Patents

Verwendung von n-methyl-n-((1s)-1-phenyl-2-((3s)- 3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl- acetamid hydrochlorid zur herstellung von arzneimitteln zur behandlung von entzündlichen darmerkrankungen

Info

Publication number
ATE214275T1
ATE214275T1 AT96109915T AT96109915T ATE214275T1 AT E214275 T1 ATE214275 T1 AT E214275T1 AT 96109915 T AT96109915 T AT 96109915T AT 96109915 T AT96109915 T AT 96109915T AT E214275 T1 ATE214275 T1 AT E214275T1
Authority
AT
Austria
Prior art keywords
hydroxypyrrolidine
diphenyl
phenyl
ethyl
methyl
Prior art date
Application number
AT96109915T
Other languages
German (de)
English (en)
Inventor
Andrew Dr Barber
Christoph Dr Seyfried
Gerd Bartoszyk
Rudolf Dr Gottschlich
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE214275T1 publication Critical patent/ATE214275T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT96109915T 1995-06-28 1996-06-20 Verwendung von n-methyl-n-((1s)-1-phenyl-2-((3s)- 3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl- acetamid hydrochlorid zur herstellung von arzneimitteln zur behandlung von entzündlichen darmerkrankungen ATE214275T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19523502A DE19523502A1 (de) 1995-06-28 1995-06-28 Kappa-Opiatagonisten für entzündliche Darmerkrankungen

Publications (1)

Publication Number Publication Date
ATE214275T1 true ATE214275T1 (de) 2002-03-15

Family

ID=7765475

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96109915T ATE214275T1 (de) 1995-06-28 1996-06-20 Verwendung von n-methyl-n-((1s)-1-phenyl-2-((3s)- 3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl- acetamid hydrochlorid zur herstellung von arzneimitteln zur behandlung von entzündlichen darmerkrankungen

Country Status (26)

Country Link
US (2) US5776972A (enExample)
EP (1) EP0752246B1 (enExample)
JP (2) JP4415075B2 (enExample)
KR (1) KR100501612B1 (enExample)
CN (1) CN1119147C (enExample)
AR (1) AR004671A1 (enExample)
AT (1) ATE214275T1 (enExample)
AU (1) AU708699B2 (enExample)
BR (1) BR9602915A (enExample)
CA (1) CA2179955C (enExample)
CO (1) CO4700454A1 (enExample)
CZ (1) CZ289805B6 (enExample)
DE (2) DE19523502A1 (enExample)
DK (1) DK0752246T3 (enExample)
ES (1) ES2171577T3 (enExample)
HU (1) HU226976B1 (enExample)
NO (1) NO309674B1 (enExample)
PL (1) PL185537B1 (enExample)
PT (1) PT752246E (enExample)
RU (1) RU2190401C2 (enExample)
SI (1) SI0752246T1 (enExample)
SK (1) SK283497B6 (enExample)
TR (1) TR199600497A2 (enExample)
TW (1) TW430557B (enExample)
UA (1) UA51615C2 (enExample)
ZA (1) ZA965480B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6303611B1 (en) * 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
JP4167302B2 (ja) * 1996-12-02 2008-10-15 杏林製薬株式会社 新規ｎ―置換ピロリジン誘導体及びその製造法
AU7133098A (en) * 1997-04-30 1998-11-24 Warner-Lambert Company Kappa opioid agonists
CA2288828A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US5760023A (en) * 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
WO2003097051A2 (en) 2002-05-17 2003-11-27 Merck Patent Gmbh Use of compounds that are effective as selective opiate receptor modulators
WO2004039785A1 (en) * 2002-11-01 2004-05-13 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
US7642274B2 (en) 2003-07-04 2010-01-05 Santen Pharmaceutical Co., Ltd. Inhibitor of pain threshold decrease
TWI334349B (en) * 2003-07-04 2010-12-11 Santen Pharmaceutical Co Ltd Pain threshold reduction depressant
EP1680115A1 (en) * 2003-10-30 2006-07-19 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
US7160902B2 (en) * 2003-11-14 2007-01-09 Adolor Corporation Amide derivatives and methods of their use
CA2682608A1 (en) 2007-03-30 2008-10-09 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
AU2013230425B2 (en) * 2012-03-05 2017-05-25 Dr.Reddy's Laboratories Ltd. Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists
CA2937656A1 (en) * 2014-01-24 2015-08-06 Cadila Healtchare Limited Novel heterobicyclic compounds as kappa opioid agonists
ES2906979T3 (es) 2016-12-21 2022-04-21 Tioga Pharmaceuticals Inc Formulaciones farmacéuticas sólidas de asimadolina
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
CA2021817C (en) * 1989-07-24 2000-09-26 William J. Mork Upholstered article of furniture with interchangeable seating module
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide

Also Published As

Publication number Publication date
NO962720D0 (no) 1996-06-27
US5977161A (en) 1999-11-02
JP5308056B2 (ja) 2013-10-09
SK84396A3 (en) 1997-04-09
SK283497B6 (sk) 2003-08-05
JP2008201794A (ja) 2008-09-04
EP0752246A2 (de) 1997-01-08
PL185537B1 (pl) 2003-05-30
TW430557B (en) 2001-04-21
AU5616296A (en) 1997-01-09
DE19523502A1 (de) 1997-01-02
ES2171577T3 (es) 2002-09-16
KR100501612B1 (ko) 2005-10-12
CN1119147C (zh) 2003-08-27
CZ186696A3 (en) 1997-01-15
US5776972A (en) 1998-07-07
HU226976B1 (en) 2010-04-28
NO309674B1 (no) 2001-03-12
CA2179955C (en) 2008-10-07
EP0752246B1 (de) 2002-03-13
HUP9601798A1 (hu) 1998-03-30
AU708699B2 (en) 1999-08-12
UA51615C2 (uk) 2002-12-16
ZA965480B (en) 1997-01-27
DK0752246T3 (da) 2002-05-13
SI0752246T1 (en) 2002-10-31
CN1145781A (zh) 1997-03-26
JPH0920659A (ja) 1997-01-21
PT752246E (pt) 2002-09-30
BR9602915A (pt) 1998-04-22
TR199600497A2 (tr) 1997-01-21
PL314996A1 (en) 1997-01-06
CO4700454A1 (es) 1998-12-29
NO962720L (no) 1996-12-30
CZ289805B6 (cs) 2002-04-17
KR970000230A (ko) 1997-01-21
JP4415075B2 (ja) 2010-02-17
EP0752246A3 (de) 1997-02-26
CA2179955A1 (en) 1996-12-29
DE59608861D1 (de) 2002-04-18
AR004671A1 (es) 1999-03-10
RU2190401C2 (ru) 2002-10-10

Similar Documents

Publication Publication Date Title
ATE214275T1 (de) Verwendung von n-methyl-n-((1s)-1-phenyl-2-((3s)- 3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl- acetamid hydrochlorid zur herstellung von arzneimitteln zur behandlung von entzündlichen darmerkrankungen
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
ATE252901T1 (de) Arzneimittel zur behandlung von entzündlichen herzkrankheiten
DE60004974D1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
ATE173468T3 (de) Substituierte dihydrobenzo(b,f)azepine, verfahren zu ihrer herstellung, ihre verwendung zur behandlung von erkrankungen des zentralnervensystems und sie enthaltende pharmazeutische zusammensetzungen
DE69612649D1 (de) Indolinonverbindungen zur behandlung von krankheiten
ATE224189T1 (de) Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69613386D1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
ATE332894T1 (de) Ein pyridin-n-oxid-derivat und ein prozess zu seiner umsetzung in pharmazeutische wirkstoffe
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
DE60029929D1 (de) VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN
DE69809284D1 (de) Immunomodulator mit anti-mikrobakteriellen und anti-mykobakteriellen eigenschaften, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen zur behandlung von mykobakteriosen sowie von chronischen und nicht-spezifischen lungenzuständen, sexuell übertragbaren krankheiten und den daraus resultierenden immunschwächen
ATE522218T1 (de) Dosierungseinheit enthaltend prostaglandin-analog zur behandlung von darmverstopfung
ATE247645T1 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
DE69522642D1 (de) Hymenialdisin und seine derivate, verfahren zur herstellung von zwischenprodukten zu ihrer synthese und besagte zwischenprodukte
DE69738320D1 (de) Verwendung von pyrolidin-derivaten zur herstellung von arzneimitteln zur behandlung von drogenmissbrauch
DE60300571D1 (de) [3,4-a:3,4-c]Carbazolderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE60017174D1 (de) Rivastigmine zur behandlung von augenerkrankungen
DE69619868D1 (de) Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung
DE69620786D1 (de) Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner